SI1578733T1 - Postopek za pridobitev rosuvastatina - Google Patents
Postopek za pridobitev rosuvastatinaInfo
- Publication number
- SI1578733T1 SI1578733T1 SI200230942T SI200230942T SI1578733T1 SI 1578733 T1 SI1578733 T1 SI 1578733T1 SI 200230942 T SI200230942 T SI 200230942T SI 200230942 T SI200230942 T SI 200230942T SI 1578733 T1 SI1578733 T1 SI 1578733T1
- Authority
- SI
- Slovenia
- Prior art keywords
- preparation
- rosuvastatin
- relates
- present
- coa reductase
- Prior art date
Links
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 title 1
- 229960000672 rosuvastatin Drugs 0.000 title 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 abstract 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 abstract 1
- 229960004796 rosuvastatin calcium Drugs 0.000 abstract 1
- LALFOYNTGMUKGG-BGRFNVSISA-L rosuvastatin calcium Chemical compound [Ca+2].CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O.CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O LALFOYNTGMUKGG-BGRFNVSISA-L 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/535—Organo-phosphoranes
- C07F9/5352—Phosphoranes containing the structure P=C-
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02781613A EP1578733B1 (en) | 2002-12-10 | 2002-12-10 | Process for the preparation of rosuvastatin |
| PCT/IB2002/005213 WO2004052867A1 (en) | 2002-12-10 | 2002-12-10 | Process for the preparation of rosuvastatin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI1578733T1 true SI1578733T1 (sl) | 2011-07-29 |
Family
ID=32500442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200230942T SI1578733T1 (sl) | 2002-12-10 | 2002-12-10 | Postopek za pridobitev rosuvastatina |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7566782B2 (sl) |
| EP (1) | EP1578733B1 (sl) |
| CN (1) | CN1742000A (sl) |
| AT (1) | ATE501126T1 (sl) |
| AU (1) | AU2002348881A1 (sl) |
| CA (1) | CA2509619A1 (sl) |
| DE (1) | DE60239428D1 (sl) |
| DK (1) | DK1578733T3 (sl) |
| HU (1) | HUP0500851A3 (sl) |
| SI (1) | SI1578733T1 (sl) |
| WO (1) | WO2004052867A1 (sl) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0401248A3 (en) | 2001-07-13 | 2004-11-29 | Astrazeneca Uk Ltd | Preparation of aminopyrimidine compounds and new intermediates |
| GB0218781D0 (en) | 2002-08-13 | 2002-09-18 | Astrazeneca Ab | Chemical process |
| GB0312896D0 (en) | 2003-06-05 | 2003-07-09 | Astrazeneca Ab | Chemical process |
| EP1562912A2 (en) | 2003-08-28 | 2005-08-17 | Teva Pharmaceutical Industries Limited | Process for preparation of rosuvastatin calcium |
| GB0324791D0 (en) | 2003-10-24 | 2003-11-26 | Astrazeneca Ab | Chemical process |
| EP1601658A1 (en) | 2003-11-24 | 2005-12-07 | Teva Pharmaceutical Industries Limited | Crystalline ammonium salts of rosuvastatin |
| ATE507209T1 (de) | 2003-12-02 | 2011-05-15 | Teva Pharma | Referenzstandard zur charakterisierung von rosuvastatin |
| EP1673351A1 (en) | 2004-07-13 | 2006-06-28 | Teva Pharmaceutical Industries Ltd. | A process for the preparation of rosuvastatin involving a tempo-mediated oxidation step |
| GB0428328D0 (en) * | 2004-12-24 | 2005-02-02 | Astrazeneca Uk Ltd | Chemical process |
| CA2591439C (en) | 2005-02-22 | 2013-03-26 | Teva Pharmaceutical Industries Ltd. | Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof |
| WO2006100689A1 (en) * | 2005-03-22 | 2006-09-28 | Unichem Laboratories Limited | Process for preparation of rosuvastatin |
| EP1869005A1 (en) * | 2005-04-04 | 2007-12-26 | Unichem Laboratories Limited | Process for preparation of calcium salt of rosuvastatin |
| CN1307187C (zh) * | 2005-05-16 | 2007-03-28 | 浙江海正药业股份有限公司 | 瑞舒伐他汀及其中间体的制备方法 |
| EP1893585A1 (en) * | 2005-06-01 | 2008-03-05 | Fermion Oy | Process for the preparation of n-[4-(4-fluorophenyl)-5-formyl-6-isopropyl-pyrimidin-2-yl]-n-methylmethanesulfonamide |
| CA2612587C (en) * | 2005-06-24 | 2013-02-19 | Lek Pharmaceuticals D.D. | Process for preparing amorphous rosuvastatin calcium free of impurities |
| CZ299215B6 (cs) * | 2005-06-29 | 2008-05-21 | Zentiva, A. S. | Zpusob výroby hemivápenaté soli (E)-7-[4-(4-fluorofenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxy-6-heptenovékyseliny |
| WO2007022488A2 (en) | 2005-08-16 | 2007-02-22 | Teva Pharmaceutical Industries Ltd. | Crystalline rosuvastatin intermediate |
| MX2007006647A (es) * | 2005-10-04 | 2007-07-25 | Teva Pharma | Preparacion de rosuvastatina. |
| EP2079712A2 (en) | 2006-10-31 | 2009-07-22 | Aurobindo Pharma Limited | An improved process for preparing rosuvastatin calcium |
| WO2008072078A1 (en) * | 2006-12-13 | 2008-06-19 | Aurobindo Pharma Limited | An improved process for preparing rosuvastatin caclium |
| EP2125754B1 (en) | 2007-02-08 | 2012-04-11 | Aurobindo Pharma Limited | Process for preparation of rosuvastatin calcium |
| US7884226B2 (en) * | 2007-07-12 | 2011-02-08 | Teva Pharmaceutical Industries, Ltd. | Purification of rosuvatatin intermediate by thin film evaporation and chemical method |
| KR101157314B1 (ko) | 2009-06-05 | 2012-06-15 | 주식회사종근당 | 로수바스타틴의 신규한 제조방법, 이 제조에 유용한 중간체 화합물 및 그의 제조방법 |
| EP2336116A1 (en) | 2009-12-16 | 2011-06-22 | LEK Pharmaceuticals d.d. | Process for the preparation of key intermediates for the synthesis of rosuvastatin or pharmaceutically acceptable salts thereof |
| KR101292238B1 (ko) | 2010-07-01 | 2013-07-31 | 주식회사유한양행 | ＨＭＧ-ＣｏＡ 환원효소 억제제 및 그의 중간체의 제조방법 |
| WO2012011129A2 (en) * | 2010-07-22 | 2012-01-26 | Msn Laboratories Limited | Novel polymorph of bis[(e)-7-[4-(4-fluorophenyl)-6-iso-propyl-2-[methyl (methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid] calcium salt |
| HU230987B1 (hu) | 2010-11-29 | 2019-08-28 | Egis Gyógyszergyár Nyrt. | Eljárás nagy tisztaságú gyógyszeripari intermedierek előállítására |
| CA2835364C (en) * | 2011-05-20 | 2018-10-02 | Astrazeneca Uk Limited | Pharmaceutical composition of rosuvastatin calcium |
| CN102358747B (zh) * | 2011-08-30 | 2012-09-19 | 浙江宏元药业有限公司 | 瑞舒伐他汀钙中间体及制备瑞舒伐他汀钙中间体和瑞舒伐他汀钙的方法 |
| WO2015074328A1 (zh) * | 2013-11-25 | 2015-05-28 | 复旦大学 | 一种瑞舒伐他汀钠的制备方法 |
| CN103601687A (zh) * | 2013-11-25 | 2014-02-26 | 复旦大学 | 一种瑞舒伐他汀钠的制备方法 |
| CN104230990B (zh) * | 2014-08-15 | 2016-05-11 | 新发药业有限公司 | 2-((4r,6s)-6-三苯基膦烯甲叉基-2,2-二取代基-1,3-二氧六环-4-基)乙酸酯及其制备方法与应用 |
| CN104630297B (zh) * | 2014-12-10 | 2018-07-06 | 江南大学 | 一种酶法非水相催化合成(r)-3-tbdmso戊二酸甲单酯及其衍生物 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2648897B2 (ja) * | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
-
2002
- 2002-12-10 HU HU0500851A patent/HUP0500851A3/hu unknown
- 2002-12-10 SI SI200230942T patent/SI1578733T1/sl unknown
- 2002-12-10 WO PCT/IB2002/005213 patent/WO2004052867A1/en not_active Application Discontinuation
- 2002-12-10 AU AU2002348881A patent/AU2002348881A1/en not_active Abandoned
- 2002-12-10 EP EP02781613A patent/EP1578733B1/en not_active Expired - Lifetime
- 2002-12-10 DE DE60239428T patent/DE60239428D1/de not_active Expired - Lifetime
- 2002-12-10 AT AT02781613T patent/ATE501126T1/de active
- 2002-12-10 DK DK02781613.1T patent/DK1578733T3/da active
- 2002-12-10 CN CNA028301951A patent/CN1742000A/zh active Pending
- 2002-12-10 US US10/537,859 patent/US7566782B2/en not_active Expired - Fee Related
- 2002-12-10 CA CA002509619A patent/CA2509619A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004052867A1 (en) | 2004-06-24 |
| EP1578733A1 (en) | 2005-09-28 |
| HUP0500851A3 (en) | 2008-02-28 |
| EP1578733B1 (en) | 2011-03-09 |
| DE60239428D1 (sl) | 2011-04-21 |
| CN1742000A (zh) | 2006-03-01 |
| US20060149065A1 (en) | 2006-07-06 |
| DK1578733T3 (da) | 2011-06-14 |
| AU2002348881A1 (en) | 2004-06-30 |
| CA2509619A1 (en) | 2004-06-24 |
| ATE501126T1 (de) | 2011-03-15 |
| HUP0500851A2 (en) | 2007-08-28 |
| US7566782B2 (en) | 2009-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60239428D1 (sl) | ||
| AU2003240517A1 (en) | Substituted pyrrolines as kinase inhibitors | |
| IL174469A0 (en) | Rearranged pentanols, a method for the production thereof, and their use as antiphlogistics | |
| YU5503A (sh) | Nesteroidni supresori zapaljenja | |
| MY147435A (en) | Process for the production of atorvastatin calcium in amorphous form | |
| PL373645A1 (en) | Pyrrolidinedione substituted piperidine-phthalazones as pde4 inhibitors | |
| YU42803A (sh) | Novi kristalni oblici atorvastatin hemi-kalcijuma i postupci za njihovo pripremanje kao i novi postupci za pripremanje drugih oblika | |
| TW200640914A (en) | Novel processes for the preparation of a benzofuran | |
| TW200518756A (en) | Process for preparation of rosuvastatin calcium | |
| AU2003225295A1 (en) | Substituted pyrroline kinase inhibitors | |
| TW200634018A (en) | Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and uses | |
| WO2012002741A3 (en) | Process for the preparation of hmg-coa reductase inhibitors and intermediates thereof | |
| MXPA04007396A (es) | Proceso para la elaboracion de inhibidores de reductasa hmg-coa. | |
| TW200724688A (en) | Process for producing atorvastatin, pharmaceutically acceptable salts thereof and intermediates thereof | |
| EP1205189A3 (en) | Combination of a prostaglandin agonist and a HMG-CoA reductase inhibitor for the stimulation of bone growth | |
| BRPI0413468A (pt) | inibidores de hmg-coa redutase baseados em pirrol | |
| IS8249A (is) | Tafla sem felur í sér flúvastatín og karmellósakalsíum | |
| YU101402A (sh) | Visoko prečišćeni preparati simvastatina | |
| WO2006122644A3 (de) | Verfahren zur herstellung von statinen | |
| SI2341054T1 (sl) | Postopek za pripravo zaviralcev HMG-CoA reduktaz | |
| WO2004048380A8 (en) | Process for the synthesis of ganciclovir | |
| MXPA02011762A (es) | Proceso para la preparacion de compuestos metales de transicion y su empleo para la polimerizacion de olefinas. | |
| MXPA03010498A (es) | Proceso para la preparacion de imipenem. | |
| MXPA03002493A (es) | Proceso eficiente para preparacion de un inhibidor del factor xa. | |
| PT1326838E (pt) | Novas formas cristalinas de um inibidor do factor xa |